loxapine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
psychoactive 1613 1977-10-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • loxapine
  • loxapin
  • oxilapine
  • loxapine succinate
  • cloxazepine
  • loxitane
  • adasuve
  • loxapine hydrochloride
  • loxapine HCl
  • loxipine maleate
An antipsychotic agent used in SCHIZOPHRENIA.
  • Molecular weight: 327.81
  • Formula: C18H18ClN3O
  • CLOGP: 3.98
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 28.07
  • ALOGS: -3.50
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
9.10 mg Inhal.powder
0.10 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Feb. 25, 1975 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 111.40 54.60 31 150 32723 2325181
Brain death 110.87 54.60 16 165 554 2357350
Neuroleptic malignant syndrome 103.66 54.60 18 163 2062 2355842
Overdose 58.66 54.60 17 164 19890 2338014
Cardiogenic shock 55.74 54.60 11 170 2480 2355424

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intestinal ischaemia 92.83 88.87 16 167 1037 1745561

Pharmacologic Action:

SourceCodeDescription
ATC N05AH01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Diazepines, oxazepines, thiazepines and oxepines
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:48561 dopaminergic antagonist
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Bipolar disorder indication 13746004 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Alcoholism contraindication 7200002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Glaucoma contraindication 23986001 DOID:1686
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Tardive dyskinesia contraindication 102449007
Seizure disorder contraindication 128613002
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Coma contraindication 371632003
Carcinoma of female breast contraindication 447782002
Pigmentary Retinopathy contraindication
Drug Induced CNS Depression contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.59 Basic
pKa2 3.24 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG ADASUVE ALEXZA PHARMS N022549 Dec. 21, 2012 RX POWDER INHALATION 7078020 Oct. 26, 2021 ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 8.62 CHEMBL CHEMBL
D(2) dopamine receptor GPCR ANTAGONIST Ki 7.68 CHEMBL CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 7.51 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 6.11 PDSP
5-hydroxytryptamine receptor 3A Ion channel Ki 6.72 PDSP
Alpha-1B adrenergic receptor GPCR Ki 7.28 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 5.85 PDSP
5-hydroxytryptamine receptor 1B GPCR Ki 6.41 PDSP
5-hydroxytryptamine receptor 1D GPCR Ki 5.46 PDSP
Histamine H2 receptor GPCR Ki 6.68 PDSP
D(1B) dopamine receptor GPCR Ki 7.12 PDSP
D(1A) dopamine receptor GPCR Ki 7.27 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 6.91 PDSP
Alpha-2C adrenergic receptor GPCR Ki 7.10 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.97 PDSP
Alpha-2A adrenergic receptor GPCR Ki 6.82 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 6.83 PDSP
5-hydroxytryptamine receptor 1A GPCR Ki 5.61 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 6.09 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 6.38 PDSP
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 8 IUPHAR
Histamine H1 receptor GPCR ANTAGONIST Ki 8.20 IUPHAR
Muscarinic acetylcholine receptor M1 GPCR IC50 5.26 CHEMBL
5-hydroxytryptamine receptor 6 GPCR Ki 7.82 CHEMBL
D(4) dopamine receptor GPCR ANTAGONIST Ki 8.31 CHEMBL
D(3) dopamine receptor GPCR ANTAGONIST IC50 7.66 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.24 PDSP
Potassium channel subfamily T member 1 Ion channel ACTIVATOR EC50 5.36 IUPHAR
Histamine H4 receptor GPCR Ki 5.30 PDSP
5-hydroxytryptamine receptor 7 GPCR Ki 7.37 CHEMBL
Adrenergic receptor alpha-1 GPCR IC50 7.74 CHEMBL
Histamine H1 receptor GPCR IC50 6 CHEMBL
D(2) dopamine receptor GPCR Ki 7.68 CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 6 CHEMBL
5-hydroxytryptamine receptor 2A GPCR IC50 8.22 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 7.80 IUPHAR

External reference:

IDSource
4019805 VUID
N0000147894 NUI
C0024056 UMLSCUI
D00794 KEGG_DRUG
376MYL4MAL UNII
54810-23-0 SECONDARY_CAS_RN
59270007 SNOMEDCT_US
4019805 VANDF
6475 RXNORM
372789006 SNOMEDCT_US
d00897 MMSL
001522 NDDF
29026 MMSL
CHEMBL831 ChEMBL_ID
DB00408 DRUGBANK_ID
2610 INN_ID
CHEBI:50841 CHEBI
3964 PUBCHEM_CID
CHEMBL1201060 ChEMBL_ID
CHEMBL1201155 ChEMBL_ID
D008152 MESH_DESCRIPTOR_UI
205 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0378-7005 CAPSULE 5 mg ORAL ANDA 12 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0378-7010 CAPSULE 10 mg ORAL ANDA 12 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0378-7025 CAPSULE 25 mg ORAL ANDA 12 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0378-7050 CAPSULE 50 mg ORAL ANDA 12 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1394 CAPSULE 5 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1395 CAPSULE 10 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1396 CAPSULE 25 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1397 CAPSULE 50 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0369 CAPSULE 5 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0370 CAPSULE 10 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0371 CAPSULE 25 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0372 CAPSULE 50 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-585 TABLET 5 mg ORAL ANDA 12 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-586 TABLET 10 mg ORAL ANDA 12 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-587 TABLET 25 mg ORAL ANDA 12 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-588 TABLET 50 mg ORAL ANDA 12 sections
Adasuve HUMAN PRESCRIPTION DRUG LABEL 1 10885-003 AEROSOL, POWDER 10 mg RESPIRATORY (INHALATION) NDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 50090-3457 CAPSULE 10 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 50090-4701 CAPSULE 10 mg ORAL ANDA 14 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 68151-2875 CAPSULE 5 mg ORAL ANDA 12 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-0346 CAPSULE 5 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-0347 CAPSULE 25 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-0416 CAPSULE 50 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-1681 CAPSULE 10 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-1792 CAPSULE 50 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-1896 CAPSULE 25 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-2120 CAPSULE 5 mg ORAL ANDA 13 sections